← Back to Clinical Trials
Recruiting NCT05598632

NCT05598632 Risk Factors for Stroke or Systemic Embolism in Chinese Patients with Non-Valvular Atrial Fibrillation Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05598632
Status Recruiting
Phase
Sponsor China National Center for Cardiovascular Diseases
Condition Atrial Fibrillation
Study Type OBSERVATIONAL
Enrollment 22,000 participants
Start Date 2023-04-18
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 120 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 22,000 participants in total. It began in 2023-04-18 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is aimed to validate the existing stroke risk stratification model for patients with atrial fibrillation (AF) (CHA2DS2-VASc Score, CHADS2 Score, ATRIA score, ABC score, etc.) and establish a new stroke risk assessment model using a nationwide AF -specific registry in China.

Eligibility Criteria

Inclusion Criteria: * 18 years of age or older; male or female. * History of documented atrial fibrillation. * Able to provide written informed consent. Exclusion Criteria: * Subjects with moderate or severe mitral stenosis or a mechanical heart valve * Subjects with previous or planned AF ablation. * Subjects with previous or planned left atrial appendage closure. * Subjects unable to cooperate with follow-up after assessment.

Contact & Investigator

Central Contact

Zhe Zheng, MD, PhD

✉ zhengzhe@fuwai.com

📞 +86-010-88396051

Principal Investigator

Zhe Zheng, MD, PhD

STUDY CHAIR

Fuwai Hospital, Chinese Academy of Medical Science

Frequently Asked Questions

Who can join the NCT05598632 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05598632 currently recruiting?

Yes, NCT05598632 is actively recruiting participants. Contact the research team at zhengzhe@fuwai.com for enrollment information.

Where is the NCT05598632 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT05598632 clinical trial?

NCT05598632 is sponsored by China National Center for Cardiovascular Diseases. The principal investigator is Zhe Zheng, MD, PhD at Fuwai Hospital, Chinese Academy of Medical Science. The trial plans to enroll 22,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology